Last updated: 2026-10-13 13:47:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
GridAI Technologies Corp. (GRDX) operates in the ELECTRIC & OTHER SERVICES COMBINED sector and is listed on NASDAQ. The stock is currently priced at $4,69, with a market capitalisation of $35,44M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,87 to $6,93. This page covers its latest market performance, valuation, price trends and company information.
$35,44M | |
$4,68 | |
$6,93 | |
$1,87 | |
$4,66 | |
4,91K | |
105,73K | |
-- | |
$6,93 | |
$1,87 | |
-- | |
-- |
GridAI Technologies Corp. (GRDX) is currently trading at $4,69 as of 2026-10-13 13:44:00, up 0,69% ($0,03) from the previous close of $4,66
During today's regular trading session, GRDX has traded between $1,87 and $6,93, with a trading volume of 4,91K shares. The current price is near the middle of today's range.
Over the past seven days, GridAI Technologies Corp. (GRDX) moved from $3,81 to $4,69, representing a gain of 23,15% ($0,88).
The stock traded between $3,40 and $5,04 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 123,09 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 55,8%
GRDX is currently trading at $4,69, placing it 55,8% of the way from its 52-week low of $1,87 to its 52-week high of $6,93. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
| Industry | ELECTRIC & OTHER SERVICES COMBINED |
| Employees | 2 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of GridAI Technologies Corp. (GRDX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.